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Table 1
Protein antigen Research data
Pneumococcal surface protein A (PspA) Protective aganist multiple pneumococcal
serotypes in mice models of invasive disease
pneumonia, and colonization. Vaccination of
healthy volunteers with PspA generated
antibodies aganist multiple strains that protected
mice aganist invasive disease. Human studies in
progess.
Pneumolysins.Pneumolysoids Protection aganist Pneuminia and increased
survival after intraperitoneal challenge. human
studies in progress
Neuraminidases (Nan) Protection aganist colonization and otitis media
Pneumococcal surface protein C (PspC) Protection aganist colonization. Protection aganist
sepsis
Pneumococcal protective protein A (PppA) Protection aganist lung infection. Protective
aganist nasopharyngeal colonization.
Pneumococcal Histidine Trial Protein D Protective aganist animal models of invasive
disease and pneumonia phase II trial reports
awaited.
IC4 antigens Protection aganist sepsis, pneumonia,
nasopharyngeal carriage.
Conclusion: Despite gaps in knowledge, Pneumococcal Protein
Vaccines could be an efﬁcacious, effective and economic alterna-
tive to currently available Pneumococcal Conjugate Vaccines for
the control of pneumococcal infections.
http://dx.doi.org/10.1016/j.ijid.2014.03.1314
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Background: In 2012 the UK experienced a national outbreak
of pertussis. The highest rates of infections were seen in infants
aged less than 3months and therewere 14 deaths in this age group
attributable to pertussis. This outbreak prompted the Department
of Health (DH) to introduce a temporary vaccination programme
for pregnant women with the aim of preventing infections in very
young infants.
This survey aimed to estimate pertussis vaccine uptake in
pregnant women and describe variations according to age, ethnic-
ity, parity and location. Informationwas also gathered on inﬂuenza
vaccine uptake.
Methods & Materials: This was a cross–sectional survey of vac-
cine uptake amongwomendelivering inmaternity units in England
over a ﬁve-day period during April and May 2013. The target sam-
ple size was at least 380 women from maternity units throughout
the country. Units were asked to complete surveys alongside birth
paperwork for all women delivering a live birth during the 5 day
period. Proportions vaccinated were calculated with 95% conﬁ-
dence intervals and multiple logistic regression used to assess
differences in uptake.
Results: Twenty–nine trusts participated in the survey, retur-
ning 1325 surveys, 85% of which contained information about
vaccine uptake. Pertussis vaccine uptake was 52.6% (range 18.1%
to 72.4%). Inﬂuenza vaccine uptake was 52.2% (range 29.0% to
70.1%). Uptake of both vaccines was signiﬁcantly higher in the
White British ethnic group than in any other at 60% (95% CI 56%
- 62%). Women in the most deprived quintile were least likely to
have had either vaccine (pertussis vaccine OR v’s least deprived
0.44, 95%CI 0.28–0.67/inﬂuenza vaccineOR0.56, 95%CI 0.36–0.86).
Ninety–eight per cent of this sample received the pertussis vaccine
within the recommended 28–38 weeks gestation timeframe.
Conclusion: The results of this survey indicate that vaccine
uptake rates in pregnant women vary signiﬁcantly across regions
and are affected by factors such as ethnicity and deprivation.
Every opportunity should be taken to promote both pertussis and
inﬂuenza vaccines to pregnant women.
http://dx.doi.org/10.1016/j.ijid.2014.03.1315
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Background: Noroviruses (NoVs) are the leading cause of acute
infectious gastroenteritis worldwide and are highly contagious.
Although commonly associatedwith contaminated food andwater,
the majority of outbreaks reported in the United States are a result
of person-to-person transmission. Vomitingmay play a critical role
in person-to-person transmission. Since environmental contami-
nation resulting from episodes of vomiting have been implicated
in norovirus outbreaks, a strategy to reduce norovirus-associated
vomiting would have public health beneﬁt.
Methods & Materials: Healthy adult subjects age 18-49 were
randomized equally to two study groups to either receive two
intramuscular injected doses of an investigational norovirus biva-
lent GI.1/GII.4 VLP vaccine or saline placebo on study days 1 and
28. On study day 56, 109 subjects were admitted to an in-patient
unit and administered an oral dose of 4.4×103 PCR units of a live
GII.4 norovirus; 56 vaccine recipients and 53 saline placebo recipi-
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ents. Symptomsof gastroenteritis, includingvomitinganddiarrhea,
occurring in the in-patient unit were recorded post-challenge.
Results: In the per protocol population, 4/48 (8.3%) of placebo
subjects and0/50 (0%)of vaccine subjects experienced severevomi-
ting (100% reduction, p =0.054). 8/48 placebo subjects (16.7%) vs. 1
vaccine subject (2.0%) experienced moderate or severe vomiting
(88.0% reduction, p =0.015), and 17/50 placebo subjects (35.4%)
vs. 4/48 vaccine subjects (8.0%) experienced mild, moderate or
severe vomiting (77.4% reduction, p =0.001). Reports of vomiting
or diarrhea of any severity were signiﬁcantly reduced in the vac-
cine group (10/50, 20%) compared with the placebo group (20/48,
41.7%; p=0.028), a 52% reduction.
Conclusion: In this study the experimental norovirus vaccine
was associated with signiﬁcant reductions in vomiting. This biva-
lent norovirus vaccinemayprovide ameans to reduce transmission
via aerosolized virus and contaminated fomites as a result of a
reduction in vomiting episodes. Field efﬁcacy studies arewarranted
to further evaluate protection.
http://dx.doi.org/10.1016/j.ijid.2014.03.1316
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immunity two years after MenAfriVacTM
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Background: In 2010, a conjugate meningococcal serogroup A
(NmA) vaccine (PsA-TT; MenAfriVacTM) was introduced in Africa’s
ﬁrst-everpreventativemeningococcalmass-vaccinationcampaign.
PsA-TT clinical trials indicate that immunity against serogroup A
disease persists for at least one year and that vaccination boosts
tetanus immunity because tetanus toxoid is used as a carrier pro-
tein. Yet, questions remain about long-term antibody persistence
againstmeningococcal serogroupAand theextentof tetanusboost-
ing in the population following introduction.
Methods & Materials: We conducted a cross-sectional
household-based age-stratiﬁed seroprevalence survey in Banconi,
Bamako, Mali in 2012. Randomly selected participants (n =800)
were eligible if they were present in Bamako and aged 1-29 years
during the 2010 vaccination campaign and if they were healthy
at enrollment. Serum samples were analyzed to determine NmA-
speciﬁc serum bactericidal antibody (rSBA) titers (reference strain
F8238), NmA-speciﬁc total IgG using enzyme-linked immunosor-
bent assay (ELISA), and anti-tetanus toxoid IgG concentrations by
ﬂorescent bead assay. The relationship between several predictive
factors and immunitywasalso assessed. Labandquestionnairedata
were analyzed with STATA v12.1.
Results: All participants were living in Bamako and eligible
to receive PsA-TT during the mass-vaccination campaign; 99.5%
reported receiving the vaccine. Nearly all participants (99.0%) had
NmA-speciﬁc SBA titers ≥8, the standard protective threshold;
97.8% had SBA titers ≥128; 89.5% had SBA titers ≥1024. SBA geo-
metric mean titers were higher in females than males except in
participants >18 years of age at vaccination. IgG levels ≥2g/mL
were found in 88.5% of participants. Forty two percent of partici-
pants had anti-tetanus IgG levels less than 1.0 IU/mL, indicating a
lack of long-term protection against tetanus. Twelve percent had
anti-tetanus IgG levels less than 0.1 IU/mL, indicating no evidence
of tetanus immunity (Fig. 1).
Fig. 1 Distribution of anti-tetanus lgG tetors by age and sex
based on age at enrollment in December 2012, Two years after
the PaA-IT mass vaccination campaign.
Conclusion: Two years after the PsA-TT mass-vaccination cam-
paign, we found evidence of persistent immunity against NmA in
Mali. However, there is a lack of evidence that PsA-TT has boosted
tetanus immunity, which may be explained by limited exposure
to primary tetanus vaccination in this population prior to PsA-TT
introduction. Our study highlights the need to go beyond clinical
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Background: Lactococcus lactis, a generally recognized as safe
(GRAS) bacterium, has become a growing interest in vaccine
research due to its non-pathogenic and non-colonizing proper-
ties. It is an attractive tool to deliver antigens by mucosal routes,
which could eventually elicit protective immunity, both systemic
and mucosal immunity. Considering inﬂuenza virus is a mucosal
pathogen, gaining entry into humans via the mucosal surface, an
ideal inﬂuenza vaccine that is able to generate both systemic and
mucosal immunity is required. The present study aims to develop a
candidate vaccine for inﬂuenza using L. lactis as a vehicle to deliver
inﬂuenza antigens.
Methods & Materials: In this study, we constructed a recombi-
nant plasmid consisting of genes encoding the truncated inﬂuenza
A virus antigenic protein, hemagglutinin (HA1), and the cell wall
bindingdomainprotein,N–acetylmuraminidase (AcmA),which are
linked together by a single-chain variable fragment (scFv) linker.
The recombinant plasmidwas transformed into Escherichia coli and
the expression of the HA1 fusion protein was induced using iso-
propyl -D thiogalactosidase (IPTG). The inclusion bodies formed
were puriﬁed under denaturing condition by afﬁnity chromatog-
raphy and refolded by dialysis. The resulting functionally active
fusion protein was surface displayed on the L. lactis. Optimizations
were performed to improve the binding capacity of the HA1 fusion
protein onto the surface of the L. lactis. This construct, the L. lactis
surface displaying HA1 fusion protein, was then administered into
